Haemonetics (HAE)
(Delayed Data from NYSE)
$91.42 USD
-0.16 (-0.18%)
Updated Jul 24, 2024 04:00 PM ET
2-Buy of 5 2
B Value B Growth F Momentum B VGM
Haemonetics (HAE) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$112.17 | $125.00 | $94.00 | 22.70% |
Price Target
Based on short-term price targets offered by six analysts, the average price target for Haemonetics comes to $112.17. The forecasts range from a low of $94.00 to a high of $125.00. The average price target represents an increase of 22.7% from the last closing price of $91.42.
Analyst Price Targets (6 )
Broker Rating
Haemonetics currently has an average brokerage recommendation (ABR) of 1.67 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by six brokerage firms. The current ABR compares to an ABR of 1.67 a month ago based on six recommendations.
Of the six recommendations deriving the current ABR, three are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 50% and 33.33% of all recommendations. A month ago, Strong Buy made up 50%, while Buy represented 33.33%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/HAE.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 3 | 3 | 3 | 3 | 3 |
Buy | 2 | 2 | 2 | 1 | 1 |
Hold | 1 | 1 | 1 | 2 | 2 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.67 | 1.67 | 1.67 | 1.83 | 1.83 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
6/12/2024 | Needham & Company | Michael Matson | Hold | Moderate Buy |
5/13/2024 | Raymond James | Andrew Cooper | Moderate Buy | Moderate Buy |
5/10/2024 | JMP Securities | David L Turkaly | Strong Buy | Strong Buy |
4/12/2024 | Barrington Research | Michael J Petusky | Strong Buy | Strong Buy |
10/24/2023 | Mizuho SecuritiesUSA | Anthony Petrone | Strong Buy | Strong Buy |
10/2/2023 | Not Identified | Not Identified | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.67 |
ABR (Last week) | 1.67 |
# of Recs in ABR | 6 |
Average Target Price | $112.17 |
LT Growth Rate | 12.00% |
Industry | Medical - Products |
Industry Rank by ABR | 98 of 252 |
Current Quarter EPS Est: | 1.03 |